ALX Oncology Reports Exit Costs and Officer Changes
Ticker: ALXO · Form: 8-K · Filed: Mar 5, 2025 · CIK: 1810182
Sentiment: neutral
Topics: restructuring, executive-changes, disposal
Related Tickers: ALXO
TL;DR
ALXO filing shows exit costs and exec shakeups - watch for strategic moves.
AI Summary
ALX Oncology Holdings Inc. filed an 8-K on March 5, 2025, reporting on cost-associated exit or disposal activities and changes in directors and officers. The filing also details compensatory arrangements for certain officers, indicating potential restructuring or executive transitions within the company as of February 28, 2025.
Why It Matters
This filing signals potential strategic shifts or financial adjustments related to disposal activities and changes in key personnel, which could impact the company's future operations and leadership.
Risk Assessment
Risk Level: medium — Changes in executive officers and disposal activities can indicate underlying business challenges or significant strategic realignments.
Key Numbers
- 20250228 — Report Date (The filing pertains to events occurring on or before this date.)
- 20250305 — Filing Date (The date the 8-K was officially submitted to the SEC.)
Key Players & Entities
- ALX Oncology Holdings Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- South San Francisco, California (location) — Principal Executive Offices
FAQ
What specific disposal activities are ALX Oncology Holdings Inc. undertaking?
The filing indicates 'Cost Associated with Exit or Disposal Activities' as an item, but does not specify the nature or details of these activities.
Were there any departures or appointments of directors or officers on February 28, 2025?
The filing lists 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' as an item, suggesting such events occurred, but details are not provided in the provided text.
What are the details of the compensatory arrangements for certain officers mentioned?
The filing notes 'Compensatory Arrangements of Certain Officers' as an item, implying changes or new agreements, but specific terms or amounts are not detailed in the provided excerpt.
What is the primary business of ALX Oncology Holdings Inc.?
ALX Oncology Holdings Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]' according to its SIC code.
Where are ALX Oncology Holdings Inc.'s principal executive offices located?
The principal executive offices are located at 323 Allerton Avenue, South San Francisco, California 94080.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 5, 2025 regarding ALX ONCOLOGY HOLDINGS INC (ALXO).